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Background: Cavopulmonary anastomosis is used for palliation of cyanotic cardiac
lesions. Postoperative development of pulmonary arteriovenous malformations can
be significant in 10% to 25% of patients. To study the basis for formation of arteri-
ovenous malformations, we developed an ovine model that reliably induces their
development 8 weeks after cavopulmonary anastomosis. Previously, we found that
cavopulmonary anastomosis inhibits the expression of pulmonary angiotensin-con-
verting enzyme and suppresses angiotensin II production.
Objective: This study examines the role of the angiotensin II receptors, type 1 and
type 2, in this setting of pulmonary vascular remodeling.
Methods: Lambs, aged 40 to 50 days, underwent cavopulmonary anastomosis. In
age-matched control animals, a sham operation was performed. Messenger RNA
and protein expression in lung specimens was measured at successive time points
after cavopulmonary anastomosis or sham operations (n = 3 at each time point).
Results: Angiotensin type 1 mRNA was maximally upregulated 2-fold at 5 weeks
after cavopulmonary anastomosis (P = .006). Expression of angiotensin type 1 pro-
tein was increased at least 2-fold at 2, 5, and 15 weeks after cavopulmonary anas-
tomosis (P = .005). Cavopulmonary anastomosis also increased angiotensin type 2
mRNA and protein expression at least 2-fold at 2 and 5 weeks (P = .02) after sur-
gical intervention. At 15 weeks, expression of angiotensin type 2 mRNA and pro-
tein was unchanged from that seen in control animals. Immunolocalization in
pulmonary tissue sections 2 weeks after cavopulmonary anastomosis revealed
markedly enhanced staining of angiotensin II receptor type 1 in vascular smooth
muscle and angiotensin II receptor type 2 in the endothelium of pulmonary arteries.
Conclusions: Rapid elevation in the expression of the type 1 and 2 angiotensin II
receptors in the affected pulmonary vasculature after cavopulmonary anastomosis
suggests their involvement in the pathologic vascular remodeling that occurs after
cavopulmonary anastomosis.
Cavopulmonary anastomosis (CPA) is performed for the palliation oftricuspid atresia and univentricular congenital heart defects. Theoriginal procedure, known as the classic Glenn shunt, makes use ofan end-to-end anastomosis of the superior vena cava (SVC) to theright pulmonary artery (RPA) to augment pulmonary blood flow.1Unfortunately, pulmonary arteriovenous malformations (AVMs)
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develop in a significant proportion of patients undergoing
CPA. Several series have demonstrated clinically significant
AVMs in up to 25% of patients after CPA.2,3 Sequelae of
these AVMs can range in severity from hypoxemia to pro-
gressive cyanosis.
Numerous reports suggest that angiotensin II (AT-II)
receptors type 1 (AT1) and type 2 (AT2) exert opposite
effects on vascular growth. In addition to mediating the
pressor effects of AT-II, AT1 induces the proliferation of
vascular smooth muscle and endothelial cells by activating
mitogen-activated protein kinases.4-6 These actions are
inhibited by the AT2 receptor through the inactivation of
mitogen-activated protein kinases, leading to suppression of
vascular cell growth and apoptosis.7 During late gestation,
the AT2 receptor is upregulated in the fetal vasculature,
inhibiting vascular smooth muscle cell proliferation.8 These
two AT-II receptors may exert opposing actions on vascular
growth in this setting of pathologic pulmonary vascular
remodeling.
To study the mechanisms responsible for this abnormal
pulmonary vascular remodeling, we have developed an
ovine model that reliably produces pulmonary arteriove-
nous shunting 8 weeks after construction of the CPA. Using
this model to investigate the basis for widespread pul-
monary vasodilation after CPA, we demonstrated the inhi-
bition of angiotensin-converting enzyme expression and
activity levels after CPA.9 A corresponding reduction in AT-
II production was also observed. This study examined the
involvement of the AT-II receptors AT1 and AT2 in the
pathogenesis of AVM formation after CPA.
Methods
Animal Model
Western sheep, aged 35 to 45 days (18-22 kg, n = 24), were
sedated with intramuscular ketamine (10 mg/kg). Lambs were
then anesthetized with inhaled isoflurane (2%), intubated, and
mechanically ventilated. After median sternotomy and pericar-
diotomy, the SVC and RPA were identified and dissected free
from their attachments. Intravenous heparin was then administered
(300 U/kg). The RPA was divided near the pulmonary bifurcation,
and the proximal end was oversewn. The SVC was divided at the
cavoatrial junction, and the atrial end was oversewn. Venous can-
nulas, sizes 16F to 20F, were placed to bypass the SVC to the right
atrium. The SVC was then anastomosed to the RPA in an end-to-
end fashion with running polypropylene sutures. The venous can-
nulas were removed, and the sternum was closed. After skin
closure, the lambs were extubated and allowed to recover.
A second group of lambs of the same age served as sham-oper-
ated control animals. The preparation and dissection was the same
as described for the Glenn cohort. The RPA was occluded with a
vascular clamp for 30 minutes. After this time, the clamp was
removed and the chest was closed, as described above.
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the
National Society of Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996. The pro-
tocol was approved by the Committee on Animal Research at the
University of California, San Francisco.
Tissue Harvest
Lambs were killed at 1, 2, 5, and 15 weeks after the operation to
obtain tissue for analysis. Animals were anesthetized and mechan-
ically ventilated, as described above. After median sternotomy, the
lambs were anticoagulated with sodium heparin (300 U/kg). The
lambs were then killed with an infusion of sodium pentobarbital.
The lungs were removed, and parenchymal samples were snap-
frozen in liquid nitrogen.
Complementary DNA Probes for Northern Blot
Analysis
Receptor subtype-specific cDNA probes were generated by means
of reverse transcription–polymerase chain reaction. Sheep lung
messenger RNA was reverse transcribed and used as a template for
the polymerase chain reaction. Primers used for the generation of
the 200-bp AT1 probe were described previously by Usui and col-
leagues.10 The 240-bp AT2 cDNA probe was generated with the
following primers: sense, 5´-CCCTTGTTTGGTGTATG-
GCTTGTCT-3´, and antisense, 5´-TGGTCACGGGTAATTCT-
GTTCTTCC-3´. Receptor subtype-specific subclones were
sequenced and then verified by means of comparison with the
known sequences in the Genbank database using the National
Center for Biotechnology Information’s BLAST software.
Northern Blot Analysis
Northern blot analysis was performed by using the conventional
radioisotope system, as described previously.11 RNA was prepared
from equal aliquots of denatured lung samples with the Tri-
Reagent kit (Molecular Research Center, Inc, Cincinnati, Ohio),
separated in a 1% agarose gel containing 2.2 mol/L formaldehyde,
and then transferred to a nitrocellulose filter. Filters were incu-
bated in prehybridization solution for 2 hours at 42°C. The AT1
(200-bp) and AT2 (240-bp) probes were prepared from cDNA
fragments that were first denatured and then radiolabeled with
phosphorous 32–labeled cytosine triphosphate. Hybridization was
then performed by incubation of the filter with 106 cpm/mL radi-
olabeled DNA probe for 18 hours. After hybridization, filters were
exposed to film-imaging plates for 24 to 72 hours at –70°C. Equal
sample loading was confirmed by means of ethidium bromide
staining and hybridization with an 18S ribosomal RNA probe.
Quantitation of expressed mRNA was performed by means of
scanning densitometry (1D Image Analysis Software; Eastman
Kodak Company, Rochester, NY).
Western Blot Analysis
Lung tissue specimens from the right lower lobe of CPA and con-
trol lambs were obtained, as described above. Specimens were
homogenized, and proteins were extracted, as previously
described.12 Proteins were then transferred to a polyvinylidene
difluoride membrane (Amersham Pharmacia Biotech Inc,
Piscataway, NJ). The membrane was soaked in Tris-buffered
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saline solution (10 mmol Tris-HCl and 250 mmol NaCl) contain-
ing 5% nonfat powdered milk and 0.1% Tween-20 to block non-
specific binding. The membrane was then incubated overnight at
4°C with a 1:200 dilution of an AT1 rabbit polyclonal antibody
(sc-1173; Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) or a
1:500 dilution of an AT2 goat polyclonal antibody (sc-7420; Santa
Cruz Biotechnology, Inc). Blots were washed and incubated for 30
minutes at 4°C with a peroxidase-conjugated secondary antibody
(1:10000 dilution; Amersham). Immunoreactivity was visualized
with the SuperSignal chemiluminescent substrate kit (Pierce,
Rockford, Ill). Quantitative assessment of band densities was per-
formed by means of scanning densitometry (1D Image Analysis
Software; Kodak).
Immunohistochemistry
Immunolocalization was performed, as previously described.12 In
brief, peripheral right lower lobe lung tissue from experimental and
control animals at 2 weeks after either CPA or a sham operation
was fixed in Histochoice fixative (Amresco, Inc, Solon, Ohio).
Tissue was then paraffin embedded, sectioned into 7-µm-thick
slices, and mounted onto glass slides. Slides were deparaffinized by
means of immersion for 6 minutes each in xylene and 100%, 95%,
70%, and 50% ethanol. Slides were washed with Tris-buffered
saline solution (50 mmol/L Tris, pH 7.6) and then incubated with
0.5% hydrogen peroxidase with 1 mg/mL of saponin for 30 min-
utes to quench endogenous peroxidases. Sections were incubated
with 4% goat serum or 4% rabbit serum for AT1 and AT2, respec-
tively, to reduce nonspecific antibody binding. Sections were incu-
bated for 18 hours with a 1:400 dilution of antibody (same as used
above for Western blot). Visualization of staining was accom-
plished with the Vectastain elite kit (Vector Laboratories, Inc,
Burlingame, Calif), with diaminobenzidine as the chromogen
(DAB kit; Zymed Laboratories, San Francisco, Calif).
Statistical Analysis
The 4 time points (1, 2, 5, and 15 weeks) were evaluated with 3 ani-
mals each in the experimental (CPA) and sham control animals
groups for a total of 12 animals in each cohort. All data are reported
as means ± SD. Analysis of statistical significance was performed
with the Student t test. All tests were paired and 2-tailed.
Results
AT1 mRNA Expression After CPA
CPA caused an early, sustained increase in AT1 mRNA
expression (Figure 1). As early as 1 week after the opera-
tion, AT1 was increased 40% ± 6% (P = .02) above values
seen in control lung tissue. Similar results were found at 2
weeks, with a 36% ± 10% increase in AT1 mRNA expres-
sion (P = .006). The upregulation was maximal at 5 weeks
after surgical intervention, revealing a 2.0 ± 0.04–fold
increase (P = .005) over that seen in sham-operated control
animals. At 15 weeks, AT1 mRNA continued to be elevated
67% ± 3% (P = .001) over that seen in control animals.
Figure 1. Pulmonary AT1 mRNA expression after CPA: representa-
tive results from Northern blot analysis for AT1 expression
depicted with corresponding densitometry results. CPA increases
AT1 mRNA expression compared with that seen in control animals
(P = .01). Data are expressed as means ± SD (n = 3 at each time
point).
Figure 2. Pulmonary AT1 protein expression after CPA: represen-
tative results from Western blot analysis for AT1 expression dis-
played with corresponding densitometry results. AT1 protein
levels are at least 2-fold higher at 1, 2, 5, and 15 weeks after CPA
compared with those seen in time-matched control animals (P =
.005). Data are expressed as means ± SD (n = 3 at each time point).
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Pulmonary AT1 protein expression approximately doubled
after CPA (Figure 2). One week after CPA, AT1 protein
expression was increased 2.1 ± 0.05–fold (P = .002). At 2
weeks after CPA, protein expression was increased 2.2 ±
0.02–fold over that of time-matched control animals (P =
.001). AT1 protein expression was elevated 2.0 ± 0.06–fold
at 5 weeks (P = .002) and 2.0 ± 0.08–fold at 15 weeks (P =
.01).
Early Increase in AT2 mRNA Expression
CPA resulted in an early, but reversible, elevation in AT2
mRNA expression (Figure 3). At 1 week after surgical inter-
vention, expression was increased 2.0 ± 0.11–fold (P = .01)
in comparison with that seen in sham-operated control ani-
mals. The greatest increase in AT2 mRNA expression was
2.9 ± 0.13–fold at 2 weeks after CPA (P = .01). At 5 weeks,
pulmonary AT2 mRNA expression was still upregulated 2.2
± 0.16–fold (P = .03). Interestingly, at 15 weeks after surgi-
cal intervention, mRNA expression was only 18% ± 9%
higher after CPA (P = .12).
AT2 Protein Expression After CPA
Pulmonary AT2 protein expression was markedly elevated
early after CPA but returned to control levels by 15 weeks
(Figure 4). CPA induced a 6.5 ± 0.90–fold increase in AT2
protein at 1 week (P = .03). Pulmonary AT2 protein was
upregulated 17.0 ± 0.73–fold at 2 weeks (P = .002) and 3.4
± 0.15–fold at 5 weeks (P = .02). Mirroring the mRNA
results, there was no statistically significant difference in
protein expression at 15 weeks between the CPA and sham-
operated groups (P = .12).
Immunolocalization of AT1 to Pulmonary Vasculature
At 2 weeks after CPA, immunohistochemistry of lung sec-
tions revealed enhanced staining of AT1 in the subendothelial
layer of the peripheral pulmonary arteries (Figure 5). The
endothelium in these specimens was unstained. In the control
specimens pulmonary arterial AT1 staining was not remark-
able when compared with background staining levels.
Immunolocalization of AT2 to Pulmonary Vasculature
Sections at 2 weeks after CPA revealed distinct AT2 stain-
ing of pulmonary arterial endothelium (Figure 6). Time-
matched control animals demonstrated only minimal
staining of the pulmonary microvascular endothelium.
Discussion
The development of pulmonary AVMs after CPA can be cat-
astrophic for the patient with cyanotic heart disease, leading
Figure 3. Pulmonary AT2 mRNA expression after CPA: representa-
tive Northern blot results for AT2 expression pictured with corre-
sponding densitometry results. AT2 mRNA expression is
upregulated transiently after CPA (P = .02). The slight increase in
expression at 15 weeks is not statistically significant (P = .12).
Data are expressed as means ± SD (n = 3 at each time point).
Figure 4. Pulmonary AT2 protein expression after CPA: represen-
tative Western blot results pictured with corresponding densit-
ometry results. AT2 protein expression is markedly upregulated
after CPA compared with that seen in sham control animals (P =
.03) at 1, 2, and 5 weeks. There was no statistically significant
change in AT2 protein at 15 weeks (P = .12). Data are expressed as
means ± SD (n = 3 at each time point).
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to further hemodynamic decompensation. Unfortunately, the
cause of pulmonary vascular remodeling in this setting is
poorly understood. It has been proposed that exclusion of
inferior vena caval blood from the pulmonary circulation
prevents the delivery of a protective hepatic factor, promot-
ing the progression of pulmonary arteriovenous shunting.
This assertion is supported by clinical observations of AVM
resolution after the inclusion of hepatic venous blood.13,14
The sustained increase in pulmonary AT1 expression
after CPA relates temporally to the development of AVMs
in our model. Arteriovenous shunting is detectable by
means of bubble contrast echocardiography in all lambs 8
weeks after CPA.9 AT1 expression is upregulated early after
surgical intervention and maintained at similar levels when
AVMs are detectable. These results suggest that AT1 may
contribute to the pulmonary vascular remodeling induced
by CPA.
Transient reexpression of the AT2 receptor after CPA is
an intriguing finding. AT2 is widely expressed in the fetal
vasculature, particularly during late gestation. After birth,
however, its levels diminish rapidly. Immunolocalization
fails to demonstrate AT2 staining in the pulmonary arterial
endothelium of the control specimens. However, after CPA,
there is widespread endothelial staining of AT2, as well as a
Figure 5. Photomicrographs of immunolocalization of AT1 in lung tissue 2 weeks after surgical intervention (original
magnification 200×). In A there is a lack of staining in the pulmonary arteriolar wall of the sham-operated control
specimens. Enhanced subendothelial staining is demonstrated in B 2 weeks after CPA. Small arrows indicate
unstained endothelium. Large arrow indicates distinct vascular smooth muscle cell staining.
Figure 6. Immunolocalization of the AT2 receptor (original magnification 200×). Shown are photomicrographs of con-
trol (A) and CPA (B) specimens 2 weeks after surgical intervention. In A arrows indicate the unstained vessel wall.
In B upregulation of AT2 after CPA is localized to pulmonary arterial endothelium. A bronchiole in the right upper cor-
ner of B is included for comparison.
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marked increase in levels of AT2 receptor protein. This reex-
pression is abolished by 15 weeks, suggesting that the
degree of AT2 expression correlates to the period of the most
active vascular remodeling, the first few weeks after CPA.
Reexpression of a fetal phenotype in pathologic settings
is not uncommon. Endothelial upregulation of expression of
the gene encoding the AT2 receptor has been demonstrated
after balloon arterial injury.15 After CPA, AT2 upregulation
may be a response to the vascular remodeling that results in
AVM formation. These results mimic the scenario during
prenatal vascular development, when AT2 is upregulated to
mediate reduction in vascular growth.
The stimulus for the enhanced expression of the AT-II
receptors after CPA is unclear. We previously found that
CPA inhibits pulmonary angiotensin-converting enzyme
activity and gene expression.9 A corresponding reduction in
AT-II production of up to 80% was also observed. Increased
expression of the genes encoding AT1 and AT2 receptors
may be attributable to reduced circulating levels of their pri-
mary ligand, AT-II.
Further study of the role of the AT-II receptor family in
pulmonary AVM formation is warranted. Selective antago-
nism of the AT1 receptor, while maintaining AT2 stimula-
tion, may be a potential therapeutic approach to the
prevention of this devastating complication of CPA.
We thank Mario Trujillo for his valuable technical assistance. 
References
1. Glenn WWL, Patino JF. Circulatory bypass of the right heart. I.
Preliminary observations on the direct delivery of the vena caval
blood into the pulmonary arterial circulation: Azygos vein-pulmonary
artery shunt. Yale J Biol Med. 1954;27:147-51.
2. Cloutier A, Ash JM, Smallhorn JF, et al. Abnormal distribution of pul-
monary blood flow after the Glenn shunt or Fontan procedure: risk of
development of arteriovenous fistulae. Circulation. 1985;72:471-9.
3. Chang RR, Alejos JC, Atkinson D, et al. Bubble contrast echocardio-
graphy in detecting pulmonary arteriovenous shunting in children
with univentricular heart after cavopulmonary anastomosis. J Am Coll
Cardiol. 1999;33:2052-8.
4. Eguchi S, Matsumoto T, Motley ED, et al. Identification of an essen-
tial signaling cascade for mitogen-activated kinase activation by
angiotensin II in cultured rat vascular smooth muscle cells. J Biol
Chem. 1996;271:14169-75.
5. Owens GK, Rabinovitch PS, Schwartz SM. Smooth muscle cell
hypertrophy versus hyperplasia in hypertension. Proc Natl Acad Sci U
S A. 1981;78:7759-63.
6. Berk BC, Wekshtein V, Gordon HM, Tsuda T. Angiotensin II stimu-
lates protein synthesis in cultured smooth muscle cells. Hypertension.
1989;13:305-14.
7. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor medi-
ates programmed cell death. Proc Natl Acad Sci U S A. 1996;93:156-
60.
8. Akishita M, Ito M, Lehtonen JYA, Daviet L, Dzau VJ, Horiuci M.
Expression of the AT2 receptor developmentally programs extracellu-
lar signal-regulated kinase activity and influences fetal vascular
growth. J Clin Invest. 1999;103:63-71.
9. Malhotra SP, Riemer RK, Thelitz S, He Y, Hanley FL, Reddy VM.
Superior cavopulmonary anastomosis suppresses the activity and
expression of pulmonary angiotensin-converting enzyme. J Thorac
Cardiovasc Surg. 2001;122:464-9.
10. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A. Regulation of
angiotensin II receptor expression by nitric oxide in rat adrenal gland.
Hypertension. 1998;32:527-33.
11. Birk E, Riemer RK. Myocardial cholinergic signaling changes with
age. Pediatr Res. 1992;31:601-5.
12. Riemer RK, Buscher C, Bansal RK, Black SM, He Y, Natuzzi E.
Increased expression of nitric oxide synthase in the myometrium of
the pregnant rat uterus. Am J Physiol. 1997;272:E1008-15.
13. Srivastava D, Preminger T, Lock JE, et al. Hepatic venous blood and
the development of pulmonary arteriovenous malformations in con-
genital heart disease. Circulation. 1995;92:1217-22.
14. Shah MJ, Rychik J, Fogel MA, Murphy JD, Jacobs ML. Pulmonary
AV malformations after cavopulmonary connection: resolution after
inclusion of hepatic veins in the pulmonary circulation. Ann Thorac
Surg. 1997;63:960-3.
15. Hutchinson HG, Hein L, Fujinaga M, Pratt RE. Modulation of vascu-
lar development and injury by angiotensin II. Cardiovasc Res. 1999;
41:689-700.
